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The field of tissue engineering is developing biomimetic biomaterial scaffolds that are showing
increasing therapeutic potential for the repair of cardiovascular tissues. However, a major opportunity
exists to use them as 3D in vitro models for the study of cardiovascular tissues and disease in addition to
drug development and testing. These in vitro models can span the gap between 2D culture and in vivo
testing, thus reducing the cost, time, and ethical burden of current approaches. Here, we outline the
progress to date and the requirements for the development of ideal in vitro 3D models for blood vessels,
heart valves, and myocardial tissue.
Introduction
Cardiovascular disease (CVD) represents a major healthcare and
economic burden and is currently the leading cause of noncom-
municable deaths worldwide [1,2]. The diseases of hypertension,
heart failure, cardiac hypertrophy, cardiomyopathy, endocarditis,
thrombosis, atherosclerosis, valvular regurgitation, and stenosis
resulted in US$320 billion expenditure in healthcare costs in 2011
in the USA alone [2]. Despite the staggering annual mortality of
17.5 million in 2012, the number of deaths has steadily declined
since the 1970s as a result of scientific advances [1,3]. Increased
funding for research in the cardiovascular field has been vital to
decelerate this progression and, with an aging population, this
research needs to continue to discover and develop new therapeu-
tics, medical devices, bioengineered replacement tissues, and sur-
gical solutions.
Research into CVD is typically carried out using 2D in vitro
culture conditions that, although relatively cheap and simple,
are a non-ideal environment to study cellular phenotype and
behaviour (Fig. 1) [4,5]. The benefit of in vitro 3D models is their
improved physiological relevance and, although imperfect, they
could serve as a bridge between 2D cultures and in vivo models, to
determine the mechanism and efficacy of targeted formulations
and devices [5]. While preclinical animal models continue to serve
as a key efficacy and safety requirement for the translation of
therapeutics, the degree of reliability achieved in reproducing
human pathophysiology in animal models is frequently inade-
quate [6]. This undoubtedly contributes to the low success rate in
developing efficient and safe therapies [7,8]. Additionally, in
recent years, we have witnessed an increased awareness of the
ethical implications of the use of animals for medical research,
encouraged by funding bodies and editors, and represented by the
concepts of the 3Rs (replacement, reduction, and refinement)
principle. These limitations in the use of both animal models
and classical in vitro 2D models have propelled the expansion of
research into new in vitro 3D cardiovascular models that allow for
greater control of variables and also a shortened experimental time
compared with in vivo models [9]. Ideal 3D models need to repli-
cate not only the anatomical macrostructure, but also the tissue
and cell-level microstructures, including appropriate cell types,
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biomimetic extracellular matrix (ECM) arrangement, and appro-
priate physiological cues. This will ensure greater precision and
reliability for translation, while reducing the number of animals
used in development (Fig. 1).
Although preclinical animal models are a necessary step to-
wards the regulatory approval of new devices and pharmaceutics,
in vitro testing can reduce translation costs and time and help to
identify the mechanism of action together with any associated
risks. Although preclinical drug screening is typically achieved
with mouse models, the human cardiac physiological response to
drugs has been shown to be markedly different to that in mice,
leading to relatively high failure rates during the clinical trial
phase. Translating a drug from a US Food and Drug Administra-
tion (FDA)-classed new molecular entity (NME) to approved
clinical product is estimated to cost between US$0.8 billion
and US$1.8 billion and typically spans 8–12 years [15], not
including the initial years of investment in basic research leading
to initial drug discovery. Little is known about the safety and off-
target effects of NMEs before human clinical trials resulting from
phylogenetic differences between humans and animal models.
This has resulted in the catastrophic failure of many Phase I drug
trials and further highlights the inadequacies of current in vitro
testing, which often are not representative of the in vivo preclini-
cal environment, let alone the clinical situation in humans. Along
similar lines, medical device development is estimated to cost
between US$31 million and US$94 million (depending on device
risk) before clinical testing [16] and, although the unwanted
effects of devices tend to be more mechanical, combination
products still need a representative in vitro testing platform.
Indeed, simpler medical devices can also benefit from an
improved in vitro testing environment, where device long-term
performance, and biocompatibility testing can be tested in a more
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FIGURE 1
Importance of the microenvironment to cardiovascular cellular phenotypes. (a) Biomechanical influences within the 3D microenvironment of the cell affect the
cellular phenotype. (b) This is illustrated within native adult cardiomyocytes by the selective localisation and/or function of their cellular proteins, which maintain
cell structure, intercellular communications, intracellular pH regulation, and Ca2+ handling. (c) Conventional static 2D culture of adult myocytes fails to preserve
the adult phenotype and (d) induces progressive dedifferentiation to a foetal phenotype. (e) The functional phenotype can be rescued, for example, by replicating
the physiological strain in cultured rat neonatal cardiomyocytes (i,ii) or by application of shear stress on cultured human aortic endothelial cells (iii,iv).
Reproduced, with permission, from [10] (b), [11], (c), [12] (d), and [13,14] (e).
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characteristic way, while being fully controllable, accessible, and
measurable.
The rapid expansion of the field of cardiovascular tissue engi-
neering has seen the development of biomaterials and neotissues
with the innate capacity to grow and remodel in vitro and, as such,
can be utilised as platforms to assess pharmaceutics and devices
before preclinical work. Currently used in vitro 3D models include
spheroids, hydrogels, ECM-derived matrices, scaffolds, and decel-
lularised tissues and/or organs [5]. For the treatment of CVD, tissue
engineering has focussed on bioengineered vessels, valves, and
regenerated myocardial tissue, with the additional potential to
enhance their regenerative capacity through the incorporation of
drugs, genetic tools, and cells. Thus, biomaterials for tissue engi-
neering provide templates upon which multiple cell types can be
cultured, and can combine genes [17] and growth factors together
with ECM constituents [18,19]. Mechanical and architectural
properties of biomaterials can be easily refined, from varying their
stiffness to their porosity and pore size [18,20,21]. In addition,
incorporation of surface-binding ligands and antibodies can en-
courage specific cell attachment, while dynamic forces can be
applied to these biomaterials, to elucidate responses also observed
in vivo [22]. The toolset available to bioengineers has now reached a
point where the in vitro replication of native tissues is achievable
through innovative biofabrication techniques, advanced cell ma-
nipulation, and the application of physiologically relevant envir-
onments through bioreactor technologies.
Here, we focus on three examples of potential 3D models of
cardiovascular tissue: vascular grafts, cardiac valves, and myocar-
dial tissue. It is envisioned that these 3D models will provide test
beds for advanced drug and device testing in addition to disease
modelling and precision medicine screening [22]. We outline the
parameters that should be considered in developing a true in vitro
model for each tissue and describe recent advances in each area.
3D in vitro models of blood vessels
Tissue-engineered blood vessels (TEBVs) hold great promise clini-
cally, where they could be utilised for coronary artery bypassing,
peripheral artery disease, or as an arteriovenous graft for haemo-
dialysis access [23]. Strides towards achieving these goals have
been made using several distinct approaches to TEBV development
with both autologous [24] and allogeneic cells [23,25], and ma-
tured through the application of physiological haemodynamic
forces within pulsatile bioreactors. The native blood vessel struc-
ture comprises a multi-lamellar architecture with a distinct ar-
rangement of endothelial cells (ECs), smooth muscle cells (SMCs),
and fibroblasts, which together maintain a normal functional
vessel. Replication of native vessels can be achieved by generating
biomimetic scaffolds comprising native polymers, such as collagen
and elastin [18], in a complex 3D tubular architecture [26], and
the correct spatial arrangement of vascular cells [27] (Fig. 2a,b).
Interestingly, the commercial approach for implantable TEBVs by
some of the leading companies in the field, including Humacyte
Drug Discovery Today  Volume 00, Number 00 May 2016 REVIEWS
DRUDIS-1796; No of Pages 9
Please cite this article in press as: Ryan, A.J. et al. Towards 3D in vitro models for the study of cardiovascular tissues and disease, Drug Discov Today (2016), http://dx.doi.org/10.1016/
j.drudis.2016.04.014
(a) (b) Unstable plaque formation
Artery lumen
Erythrocyte
Thrombus
Endothelium
Platelets
Plaque rupture
Internal elastic lamin
Migration
of SMCsSmooth muscle celltransforms
into the foam cell
LymphocyteFoam cell dies
releases
lipid debris
Transforms
into foam cell
Fibroblasts
SMCs
ECs Low density lipoprotein (LDL)
Smooth muscle cell migration
Transformed macrophage into the foam cell
Transformed muscle cell into the foam cell
Macrophage
Oxidised LDL
Macrophage
takes up
oxidised LDL
LDL oxidizes
Low-density
lipoprotein (LDL)
Monocyte migrates
into the tunica intima
Fib
rou
s c
ap
Tunica intima
Tunica media
Core
(c)
Drug Discovery Today 
FIGURE 2
Atherosclerotic disease progression and in vitro device testing. The healthy vessel wall (a) is infiltrated by macrophages, which begin to form foam cells and initiate the
degenerative cascade, which eventually results in an unstable atherosclerotic lesion (b). The complex process of atherosclerotic lesion progression has proven difficult
to replicate in vitro. Radiographic image of a stent deployed within a blood vessel mimic (v) [28]. Abbreviations: EC, endothelial cells; SMC, smooth muscle cells.
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Inc. and Cytograft Tissue Engineering Inc, has progressed towards
growing TEBVs in vitro and then decellularising these TEBVs to
reduce costs and complexity, and to ease the regulatory pathway.
The advances made towards the realisation of a clinically available
vascular graft have left the field with the knowledge and toolsets
required to generate high-fidelity vascular analogues in vitro that
could also be used preclinically in vitro.
One of the initial areas of interest for in vitro TEBV models was
for pharmacological studies. Nicolas L’Heureux, one of the pio-
neers of TEBVs, demonstrated in 1998 the ability to create triple-
layered grafts [28], before generating individual vascular tissue
layers for pharmacological studies of contraction [29]. These me-
dial layer equivalents were generated from human vascular SMCs
and were shown to be responsive to multiple vasoconstrictors (e.g.
histamine, ATP, bradykinin, and UTP) in a concentration-depen-
dent manner. This reduction in complexity for a pharmacological
study was an interesting approach because it allowed the physio-
logical response of a single cell type and/or tissue layer to be
determined. A similar approach was utilised to create medial
layer-equivalent TEBVs that maintained the subtle differences in
receptor expression and response to endothelin as the native
vessels from which the cells were extracted [30].
The innermost layer of blood vessels, the tunica intima, is lined
with ECs, a vital component to maintain haemostasis and control
vascular permeability. However, the deployment of intravascular
devices, such as stents, is known to damage the EC lining of vessels
and so all the device deployment studies to date have first focused
on generating a model vessel containing a confluent EC monolay-
er [31–33] (Fig. 2c). While these studies used EC monolayers that
were preconditioned via a bioreactor flow loop system to simulate
in vivo haemodynamics, the underlying vessels utilised thus far for
device testing have been of a synthetic nature, such as expanded
polytetrafluoroethylene [31,32] or silicone [33]. Consequently,
there exists a need for an in vitro TEBV model that can not only
simulate EC damage during device deployment, but also contains
a SMC-seeded tunica media (middle layer) to simulate restenosis,
the narrowing of vessels, which is commonly caused by neointi-
mal hyperplasia of SMCs because of device deployment [34].
In conjunction with device testing, the use of a TEBV as an in
vitro model might also be a useful platform to study CVDs, such as
atherosclerosis, which alone is responsible for 67.8% of CVD-
related deaths [35]. Although our ability to combat the clinical
manifestations of atherosclerosis with advanced treatment modal-
ities has resulted in reduced disease mortality [36], the prevention
and reversal of the disease itself remains unfulfilled. Atherosclero-
sis is a complicated disease with the pathogenesis involving ECs,
SMCs, lipoproteins, and macrophages over a time period often
spanning decades (Fig. 2a,b). Early in vitro models of the disease
utilised permeable membranes for the co-culture of ECs and SMCs,
and successfully demonstrated the transmigration of monocytes
across the EC layer and uptake of low-density lipoprotein (LDL) to
form foam cells [37]. Although these were important steps in the
field, they do not accurately represent the 3D environment of
native vasculature cells. Some progress towards a biomimicking
atherosclerotic model was made with the creation of flat 3D fibrin
gels, which were capable of long-term culture and facilitated the
formation of foam cells [38]. Utilising this model enabled exami-
nation of LDL-induced expression of interleukin 8, a neutrophil
chemokine, by SMCs and the subsequent recruitment of neutro-
phils into the subendothelial space, a previously unproven associ-
ation [39].
An additional important factor in the progression of atheroscle-
rosis is the effect of flow-induced shear stress, and cyclical strain
[40]. A 3D tubular architecture is required to impart these forces
accurately, in conjunction with pulsatile flow bioreactors, which
can control the fluid forces applied. Such a model has been shown
to be capable of generating the first 3D tubular TEBV, which
mimicked the early stages of atherosclerosis under dynamic cul-
ture conditions [41]. With few research groups seemingly tackling
the issue of creating high-fidelity atherosclerotic disease models,
the progress in the field has understandably been slow to date.
Furthermore, because vulnerable plaque lesions take decades to
form naturally in vivo, the next step in this research must be
to drastically accelerate the lesion-forming process in vitro
(Fig. 2b) to allow for analysis of the parameters that affect the
progression of this disease. Having a representative 3D model of
atherosclerosis would allow the in vitro testing of therapeutics that
could directly target lesions in a controlled and measurable way. In
fact, the targeting of atherosclerotic lesions via nanoparticles has
recently been modelled in vitro with a microfluidic system contain-
ing an atherosclerotic endothelium with controlled permeability,
opening the field to further use of these models for modelling
targeted drug delivery [42]. Transferring this type of testing into a
larger 3D in vitro model is possible using the techniques developed
for TEBVs.
Although great advances have been made in the field towards
realising the use of TEBVs as implantable grafts to replace diseased
or damaged tissue, the tissue complexity achieved is far beyond
that utilised for device testing and disease modelling. This high-
lights the disconnect between the in vitro models generated, which
display poor physiological relevance, and those that the field is
undoubtedly capable of generating for use as implantable TEBVs.
3D in vitro models of heart valves
With an increasing aging population and no proven pharmaceu-
tical therapies to decelerate it, valvular disease is predicted to
become the next global epidemic [43], with a prevalence of disease
observed in aortic and mitral valves. A representative in vitro 3D
model of aortic heart valves would help elucidate the mechanisms
driving calcific aortic valvular disease (CAVD), a disease that
affects 2.8% of the population [2], or endocarditis (bacterial and
viral), both of which have limited treatment options [44]. Mitral
valves also have calcification of their chordae tendineae, annulus,
and the valve leaflets, requiring valve repair or replacement.
Tissue-engineering strategies for heart valves are varied, with a
multitude of cell sources [45], scaffold materials [19], and fabrica-
tion strategies currently under investigation [46–50]. However, for
a tissue-engineered valve to serve as an in vitro 3D model, ECM-
derived scaffold materials and native valvular cells would be a
requisite starting point, followed by biomimetic ECM structure
and appropriate mechanical properties. Many tissue-engineered
valves utilise cell sources such as umbilical vein cells and mesen-
chymal stem cells [45], cell types that would be suboptimal in an in
vitro 3D model of the valve, but have advantages for engineered
autologous tissues because of their ability to differentiate and act
as valvular-type cells. However, many of the sophisticated valve
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scaffolds that have been developed through tissue engineering
could be easily populated with more representative cells for an in
vitro model. Here, we concentrate on the aortic valve, because most
tissue-engineering strategies that could be used as in vitro models
are focussed on this structure.
The highly organised configuration of the aortic valvular ECM
prevents regurgitation of blood through coaptation of its three
cusps or leaflets, each of which has the same trilayered micro-
structure. The fibrosa, spongiosa, and ventricularis layers occupy
an overall thickness of approximately 1 mm and comprise colla-
gen, elastin, and glycosaminoglycans in a specific arrangement
(Fig. 3). Valvular interstitial cells (VICs) occupy the tissue layers,
maintaining valve homeostasis through regulation of cellular
proliferation and tissue remodelling. Although VICs are a fibro-
blastic cell type, they have five different phenotypes, and can
convert from one form to another [51]. The nonthrombogenic
interface of the valves between the blood and VICs is maintained
by valvular endothelial cells (VECs). At a basic structural and
functional level, the valvular and vascular endothelium appear
similar; however, comparisons have identified hundreds of sig-
nificantly different genes [52]. In dynamic culture, their response
to shear and pressure is different and their transcriptional gene
expression profile also differs when exposed to the same mechan-
ical environment [52–54]. VECs regulate the activation of VICs
through mechanotransduction, nitric oxide, vasodilatory pros-
tanoids, and endothelin 1 [51].
In vitro, individual cellular components of the complex valve
structure have been examined in isolation using 3D models, with
an aim of understanding the mechanisms driving CAVD. The
expression of growth factors by VICs has been examined at the
edge of a damaged VIC layer using an ‘in vitro wound model’ [55],
advancing understanding of VICs in a simple model system. 3D
structures, such as PEG hydrogels, have been used to characterise
VICs in isolation [56,57] and the reaction of VIC to substrate
stiffness [57–60]. However, without the interactions of VECs with-
in the correct ECM structure, these 3D models are limited.
The creation of a layered co-culture system with the physiologi-
cal ECM components and structure is challenging, although
simple VIC/VEC co-culture studies have been carried out. An
interesting method using magnetic levitation was proposed by
Grande-Allen’s group [63], who also proposed a synthetic PEG
hydrogel system to encourage layer-specific cell growth [64]. Col-
lagen gels incorporating glycosaminoglycans have been used in
both single cell cultures and co-cultures to investigate the inter-
actions of ECM proteins with cells [65–68]. However, without the
correct ECM structure found in vivo, the addition of these matrix
components facilitates limited learning, because their structure,
mechanical properties, and orientation are not considered.
The introduction of dynamic culture is a necessary parameter to
investigate cardiovascular cell interactions, but further compli-
cates any experimental setup and, as such, limited models have
been developed to date. Collagen hydrogels have been used to
assess VIC response to cyclic strain [69] and VIC/VEC response to
shear stress [70,71] but again, because of the lack of a biomimetic
ECM structure, these studies are limited. Other dynamic studies
focussed on the development of tissue-engineered valve replace-
ments; however, these studies have not utilised VICs [72] because,
for tissue-engineered valves, this cell source would be unavailable
when developing valves for patients. However, there is the
potential to use these scaffold arrangements to study VIC–VEC
interactions in dynamic culture. A porous fibrin-collagen-glycos-
aminoglycan scaffold was recently developed [20] that shows
potential for use as a platform to examine VIC–VEC interactions
in dynamic culture. This model system, created from natural
materials, has mechanical properties that can be altered as per
experimental needs, can be formed into any shape, used within a
dynamic environment, and can facilitate homogenous VIC distri-
bution while maintaining a monolayer of VECs [73].
CAVD pathogenesis is far from fully understood; it is hypothe-
sised to result from both injury to the valve and the subsequent
activation of cells to repair the injury, while also involving the
reactivation of developmental processes, such as the endothelial-
to-mesenchymal transformation (EMT) [74]. A complete under-
standing of CAVD will allow for the development of suitable small-
molecule/drug treatment options for this disease. Representative
3D models of the aortic valve can elucidate that knowledge
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FIGURE 3
The native aortic valve structure is multi-layered and anisotropic. This structure must be replicated in an in vitro 3D model to ensure correlation with the structure
of the native valve. (a) The aortic valve leaflet comprises a distinct extracellular matrix (ECM) trilayered structure that (b) aligns and crimps to enable opening of
the valve during systole. During diastole, the valve cusp sustains a large pressure difference across each side of the cusp and the ECM is strained to sustain this
force. The layered structure of the valve is shown here with the fibrosa (f ), spongiosa (s), and ventricularis (v) having a distinct morphology with the valvular
endothelial cells covering the ventricular and aortic side of the valve.
Reproduced, with permission, from [61,62].
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through the identification and understanding of cellular and ECM
changes in early disease states. This could lead to use of 3D models
for the controlled, advance screening of various treatments to
address the changes seen in the diseased state. These treatments
might range from small-molecule/drug treatments to devices, and
a suitable 3D model would be an invaluable tool for assessment of
these innovations. Initial observations on individual cell layers
have shown interactions between serotonergic medications and
the development of valvular heart disease [75]. Similarly, the
mutations in the signalling and transcriptional regulator NOTCH
1 have been widely investigated because of the association be-
tween NOTCH 1 and a range of developmental aortic valve anom-
alies [76,77]. Although many of these developmental studies are
performed in vivo, the use of an in vitro 3D model with correct ECM
architecture and human cells could progress knowledge and lead
to the identification of a treatment for CAVD. Modification of the
geometry used can allow optimisation for pulmonary, mitral, and
tricuspid valves, enabling examination of more individual valve-
specific conditions.
Given the distinctiveness of valvular cells, the architecture of
the valve itself, and the haemodynamic forces experienced by the
tissue, a complete 3D model of the aortic valve can only be found
in vivo, and explanted human and porcine valves have been
studied to understand cellular dysfunction in both aortic and
mitral valves [78,79]. The next step is to have a representative
in vitro 3D model to facilitate research into the causes and treat-
ment of valve calcification, which would accelerate progress in
combating this increasingly prevalent disease.
3D in vitro models of myocardial tissue
Modelling of cardiac tissue response in vitro is important because it
enables the examination of CVD and potential drug responses
before progressing to costly clinical trials. The myocardium is
involved in the propagation of electrical signals and also in force
generation through the cardiomyocyte-rich tissue and so can be
considered a functional unit of the heart wall. Clinical manifesta-
tions of myocardial loss and/or dysfunction are traditionally ob-
served after ischaemic events, such as myocardial infarction,
resulting in the loss of functionally viable myocardium, which
can lead to the downward spiral to heart failure.
2D monolayers of cardiomyocytes have been used successfully
to estimate drug-induced apoptosis and cardiac tissue damage
and/or breakdown (troponin and lactate dehydrogenase release)
[80]. However, these studies have been performed using static
cultures of immature, neonatal cardiomyocytes, which are not
representative of the adult, fully differentiated, cell. In addition, it
is widely known that adult cardiomyocytes dedifferentiate and do
not survive medium-term culture (Fig. 1). Moreover, acquired or
inherited cardiomyopathies are often characterised by impaired
functional characteristics, with cardiomyocyte contractile forces
and kinetics helping to determine final ejection fractions. There-
fore, 3D myocardium models are an important toolset with which
to determine the mechanism of action of cardiac drugs, potential
pro-arrhythmic effects of drugs, protein knockdown studies, in
conjunction with heart disease modelling.
Tiburcy et al. [81] showed that 3D culture can recapitulate
suitable environmental conditions to model hypertrophic cardiac
growth by inducing terminal differentiation of neonatal rat car-
diomyocytes and remodelling of a collagen type I-based hydrogel.
Further advancement of collagen hydrogel-based models has been
achieved by moulding microtissues around microfabricated sili-
cone posts (Fig. 4a,b), where the tissue contraction force genera-
tion can then be determined through the deflection of the silicone
posts [82]. Although these studies utilised rat neonatal cardiomyo-
cytes, a more promising approach might be the creation of a
human pluripotent stem cell-based model to generate adult hu-
man cardiomyocytes. Thavandiran et al. [83] reported the ability to
create cardiac microtissues using human embryonic stem cells,
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FIGURE 4
Engineering functional cardiac microtissues and simulation stress-induced maturation. (a) Engineered cardiac microtissues comprising neonatal mouse
cardiomyocytes in a collagen I hydrogel that was contracted around polydimethylsiloxane microposts in a uniaxial or biaxial configuration. (b) Collagen (green)
and cell (red) orientation during maturation was then tracked via fluorescent probes. (c) The stress-induced alignment and maturation of these cardiac
microtissues can also be accurately simulated to inform future design considerations for these tissues.
Adapted, with permission, from [83,86].
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and further improved tissue remodelling and physiological
responses via electromechanical stimulation. Furthermore, the
stress-induced alignment and maturation of these tissues could
be accurately simulated (Fig. 4c). Robust cardiomyocyte derivation
from human induced pluripotent stem cells (iPSC-CM) has also
been achieved through the canonical Wnt pathway [84] and, as
such, represents an accessible and reproducible cell source that has
been successfully utilised to generate myocardial tissue models. An
iPSC-CM-based 3D tissue model of long QT syndrome demonstrat-
ed increased drug-induced cardiac toxicity and increased arrhyth-
mic signs in the 3D tissue model versus the current industry
standard 2D model, thus highlighting the inadequacies of current
standard models for risk estimation [85].
An interesting approach to cardiac disease modelling is the
combination of cardiac microtissues with microfluidic-based sys-
tems to potentially increase throughput and reduce future assay
costs [87]. Such a system was utilised effectively to create a 3D
pathophysiological model of Barth’s syndrome, an X-linked ge-
netic disorder characterised by cardiomyopathy, by first generat-
ing iPSC-CMs from patients with Barth’s syndrome [88]. This 3D
disease model was then incorporated into a microfluidic-based
heart-on-a-chip platform, where the functional characteristics of
the disease, such as reduced contractile stress, were accurately
reproduced before correction of the disease-causing gene TAZ with
modRNA therapy to restore contractile function [88]. The power of
in vitro pathophysiological models can be enhanced via CRISPR/
Cas9 genome editing to generate isogenic human cell line controls
that reproduce disease state phenotypes, and arguably represents
the next step in the field [89].
Cardiotoxicity is of major concern to myocardial tissue, with
many drugs having been pulled from market because of this issue,
including anticancer drugs [90], diabetes drugs, and even those
targeting CVD itself [91]. To overcome this difficulty, there has
been an increasing switch towards utilising human cells to create
complex in vitro tissue models as platforms for drug testing.
Cardiotoxicity can be induced by anthracyclines, such as doxo-
rubicin, or more targeted therapies, such as HER2 inhibitors (e.g.
trastuzumab) used for breast cancers. Furthermore, the pro-
arrhythmic effect of drugs on cardiac tissue has been effectively
modelled by Davis et al. [92]. Although there is a clear need for the
utilisation of cardiac tissue for drug safety and efficacy testing, the
mechanism of cardiac drug action could be determined with 3D
myocardium models. For example, one of the mechanisms of
action of atorvastatin was only determined through the use of a
3D myocardial tissue model in 2006, yet the drug had been
utilised clinically for a decade previous to this study [93]. With
increasing activity in the development of advanced therapeutics
utilising approaches such as gene therapy and miRNA delivery,
these novel in vitro assays could soon become one of the gold
standards for safety, efficacy, and mechanistic studies for cardiac
applications.
State-of-the-art and future directions
The field of tissue engineering is developing biomimetic bioma-
terial scaffolds that are showing increasing therapeutic potential
for the repair of cardiovascular tissues. However, because of the
greater correlation between these models and the physiological
conditions found in the in vivo environment, a major opportunity
exists to use them as in vitro 3D models for the study of cardiovas-
cular structures and disease interventions. These in vitro models
can help span the gap between 2D culture and in vivo testing, thus
reducing the cost, time, and ethical burden of current approaches.
The use of biomaterials as 3D models to facilitate greater under-
standing of CVD tissues can build upon other cutting-edge
approaches, including miniaturised in vitro 3D microfluidics mod-
els, such as organs-on-a-chip, which facilitate fast repeatable
results, while minimising cost and waste [90,94]. Combining
multiple tissue models to create a ‘body-on-a-chip system’ is seen
by many to be the ultimate goal to replicate the complex multi-
organ crosstalk and reactions observed in vivo [95]. However, the
biological complexity of these systems is often comparatively
simple compared with the multi-layered and multicellular macro-
scale tissue-engineered constructs currently being developed in
the regenerative medicine field [96]. Increased translation of na-
tive tissue complexity into the micron scale used within micro-
fluidic platforms might allow greater correlation between these
in vitro testing platforms and native tissues. However, not all
testing needs to be completed in a lab-based setting and often
the effect of multiple parameters can be projected using in silico
simulations. A recent review in this journal profiled the work being
completed using in silico models of adverse drug reactions, various
protein targets, and gene expression markers to facilitate drug
screening in vitro [97]. This work could be augmented and further
validated using the proposed in vitro 3D models discussed here
leading to powerful and safe drug screening methods.
Although the advantages of in vitro 3D models have been out-
lined here, there are situations where in vivo animal models remain
indispensable, because of the shared pathogenesis and multiple
manifestations of different diseases [98]. For example, Marfan
Syndrome is well represented using mutagenic mouse models
deficient in fibrillin 1 and these models have aided in the discovery
of new drug-based treatments to curb the progression of the disease
[99,100]; the progression of bicuspid aortic valve disease is also well
replicated using mutagenic mice, which enable the natural progres-
sion of multiple pathologies, something even the most accurate in
vitro 3D model of an individual cardiovascular component cannot
achieve [98].
Concluding remarks
In summary, we propose that tissue-engineered biomimetic bio-
material scaffolds can not only serve a therapeutic in regenerating
damaged or diseased organs and tissues, but also enable more
robust testing of new technologies before in vivo testing. Increased
collaboration between pharmaceutical and medical device com-
panies with tissue-engineering researchers could see further devel-
opment and validation of these models, facilitating a universally
beneficial more efficient, safe, and ethical route to market for new
devices, drugs, and combination products.
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